Implementation issues affecting patient access to Medicare covered pharmaceuticals and biologics, including reimbursement adequacy, Medicare Parts B and D benefit parameters, coverage, and reimbursement requirements, including related provisions in H.R. 5376, the Inflation Reduction Act of 2022 (P.L. 117-169): Title 1, Subtitle B - Prescription Drug Pricing Reform: Part 1, Lowering Prices Through Drug Price Negotiation; Part 2, Prescription Drug Inflation Rebates; and Part 3, Part D Improvements and Maximum Out-of-Pocket Cap for Medicare Beneficiaries.
Enhance Center for Medicare & Medicaid Innovation quality initiatives and patient access to Medicare Part B covered drugs, including advocacy related to the Most Favored Nation and related demonstration initiatives.
340B Program issues and patient access to pharmaceuticals, including related provisions in H.R. 3290, to amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program."
Legislative issues associated with patient access to treatment, including: the CMMI Most Favored Nation and related demonstration initiatives; and step therapy, including related provisions in H.R. 2630/S. 652, the Safe Step Act.
Medical Supply Chain, including issues related to a new rating system; targeted action to support the diversification of certain supplies; additional funding to the Strategic National Stockpile (SNS) and more diverse stockpile; increasing flexibility for supply chains.
Enhanced FDA reporting and risk mitigation plans for certain medicines.
Incentives for antimicrobial and antiviral research and novel product development.
Duration: April 1, 2008
to
present
General Issues: Medicare/Medicaid , Health Issues , Trade (Domestic & Foreign) , Taxation/Internal Revenue Code
Spending: about $3,780,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2008: U.S. Senate, House of Representatives, Centers For Medicare and Medicaid Services (CMS), Centers For Medicare and Medicaid Services (CMS)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Richard Sullivan Special Assistant to House Majoirty Leader
Jim McCrery Former Member of Congress, Louisiana 4th
Ranking Member, House Ways and Means Cmte
Cmmittee Member, Joint Cmte on Taxation
Committee Member, Joint Cmte on Taxation
Drew Goesl Chief of Staff, Cong. Mike Ross
Communications Dir., Sen. Blanche Lincoln
Sara Franko Legislative Director/AA, Rep. Ted Strickland
AA, Rep. Gerald Kleczka
LD/LA, Rep. Dennis Eckart
Luke Hatzis LD & LA, Cong. Peter Roskam
Republican Clerk, House Rules Committee
Legislative Aide, House Republican Conference
Floor Assistant, Speaker J. Dennis Hastert
Martin Gold Floor Advisor & Counsel, Senate Majority Leader Bill Frist.
Ann Jablon Chief of Staff, Rep. Richard Neal.
Dena Battle Leg. Director, Rep. Dave Camp
Leg. Director, Rep. Nick Smith
John O'Neill Policy Director/Counsel, Senate Minority Whip
Tax Counsel, Senate Finance Committee
James Gould Staff Director, Senate Finance Committee
Tucker Shumack Tax/Finance Counsel, Sen. Cmte on Small Business
LA, Sen. Johnny Isakson/LA, Sen. Paul Coverdell
Catherine Finley Staff Director, Senate Aging Committee
Sr. Health Policy Advisor, Senator Gordon Smith
Legislative Correspondent, Senator DeWine
Sr. Health Policy Advisor, Sen. Gordon Smith
Sr. Health Policy Advisor, Sen. Olympia Snowe
Aaron Cohen Chief of Staff & Legislative Assistant, Sen. John Ensign; Legislative Aide, Sen. Richard Bryan; Legislative Corresp., Sen. Richard Bryan.
Caitlin Shannon Deputy Chief of Staff, Rep. Devin Nunes.
Joseph Eannello Legislative Director, Rep. Kevin Yoder; Legislative Assistant, Rep. Jerry Weller.
Robert Diamond Special Assistant to the President and Director of Private Sector Engagement, President Barack Obama.
Jeffrey Carroll Staff Director House Energy and Commerce Committee; Chief of Staff, Rep. Frank Pallone; Legislative Director, Rep. Frank Pallone; Legislative Assistant, Rep. Frank Pallone.
Nick Bouknight Deputy Chief of Staff, Rep. Kevin McCarthy; Deputy Chief of Staff/ Communications Dir., Rep. Kevin McCarthy; Press Sec., Rep. Kevin McCarthy; Press Sec., Rep. Bill Thomas; Deputy Press Sec., Ways and Means Cmte.; Press Asst., Ways and Means Cmte.
John D. Raffelli n/a
Jim Gould n/a
Denise Henry n/a
Shannon Finley n/a
Zahra Buck n/a
David Jones n/a
DAN PAPDOPOULOS n/a
SARA L. FRANKO n/a
Mike Hoak n/a
Denise Henry Morrisey n/a
Kate Abramson n/a
John D. Raffaelli n/a
De'Ana Dow n/a
Caitlin Canter n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, Capitol Counsel LLC lobbied for Genentech , earning $50,000. The report was filed on April 20.
Original Filing: 301568378.xml
Lobbying Issues
Implementation issues affecting patient access to Medicare covered pharmaceuticals and biologics, including reimbursement adequacy, Medicare Parts B and D benefit parameters, coverage, and reimbursement requirements, including related provisions in H.R. 5376, the Inflation Reduction Act of 2022 (P.L. 117-169): Title 1, Subtitle B - Prescription Drug Pricing Reform: Part 1, Lowering Prices Through Drug Price Negotiation; Part 2, Prescription Drug Inflation Rebates; and Part 3, Part D Improvements and Maximum Out-of-Pocket Cap for Medicare Beneficiaries.
Enhance Center for Medicare & Medicaid Innovation quality initiatives and patient access to Medicare Part B covered drugs, including advocacy related to the Most Favored Nation and related demonstration initiatives.
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B Program issues and patient access to pharmaceuticals, including related provisions in H.R. 3290, to amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program."
Legislative issues associated with patient access to treatment, including: the CMMI Most Favored Nation and related demonstration initiatives; and step therapy, including related provisions in H.R. 2630/S. 652, the Safe Step Act.
Medical Supply Chain, including issues related to a new rating system; targeted action to support the diversification of certain supplies; additional funding to the Strategic National Stockpile (SNS) and more diverse stockpile; increasing flexibility for supply chains.
Enhanced FDA reporting and risk mitigation plans for certain medicines.
Incentives for antimicrobial and antiviral research and novel product development.
Agencies Lobbied
U.S. Senate
4th Quarter, 2023
In Q4, Capitol Counsel LLC lobbied for Genentech , earning $50,000. The report was filed on Jan. 19.
Original Filing: 301530262.xml
Lobbying Issues
Implementation issues affecting patient access to Medicare covered pharmaceuticals and biologics, including reimbursement adequacy, Medicare Parts B and D benefit parameters, coverage, and reimbursement requirements, including related provisions in H.R. 5376, the Inflation Reduction Act of 2022 (P.L. 117-169): Title 1, Subtitle B - Prescription Drug Pricing Reform: Part 1, Lowering Prices Through Drug Price Negotiation; Part 2, Prescription Drug Inflation Rebates; and Part 3, Part D Improvements and Maximum Out-of-Pocket Cap for Medicare Beneficiaries.
Enhance Center for Medicare & Medicaid Innovation quality initiatives and patient access to Medicare Part B covered drugs, including advocacy related to the Most Favored Nation and related demonstration initiatives.
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B Program issues and patient access to pharmaceuticals, including related provisions in H.R. 3290, to amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program."
Legislative issues associated with patient access to treatment, including: the CMMI Most Favored Nation and related demonstration initiatives; and step therapy, including related provisions in H.R. 2630/S. 652, the Safe Step Act.
Medical Supply Chain, including issues related to a new rating system; targeted action to support the diversification of certain supplies; additional funding to the Strategic National Stockpile (SNS) and more diverse stockpile; increasing flexibility for supply chains.
Enhanced FDA reporting and risk mitigation plans for certain medicines.
Incentives for antimicrobial and antiviral research and novel product development.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2023
In Q3, Capitol Counsel LLC lobbied for Genentech , earning $50,000. The report was filed on Oct. 18, 2023.
Original Filing: 301504675.xml
Lobbying Issues
Implementation issues affecting patient access to Medicare covered pharmaceuticals and biologics, including reimbursement adequacy, Medicare Parts B and D benefit parameters, coverage, and reimbursement requirements, including related provisions in H.R. 5376, the Inflation Reduction Act of 2022 (P.L. 117-169): Title 1, Subtitle B - Prescription Drug Pricing Reform: Part 1, Lowering Prices Through Drug Price Negotiation; Part 2, Prescription Drug Inflation Rebates; and Part 3, Part D Improvements and Maximum Out-of-Pocket Cap for Medicare Beneficiaries.
Enhance Center for Medicare & Medicaid Innovation quality initiatives and patient access to Medicare Part B covered drugs, including advocacy related to the Most Favored Nation and related demonstration initiatives.
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B Program issues and patient access to pharmaceuticals, including related provisions in H.R. 3290, to amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program."
Legislative issues associated with patient access to treatment, including: the CMMI Most Favored Nation and related demonstration initiatives; and step therapy, including related provisions in H.R. 2630/S. 652, the Safe Step Act.
Medical Supply Chain, including issues related to a new rating system; targeted action to support the diversification of certain supplies; additional funding to the Strategic National Stockpile (SNS) and more diverse stockpile; increasing flexibility for supply chains.
Enhanced FDA reporting and risk mitigation plans for certain medicines.
Incentives for antimicrobial and antiviral research and novel product development.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2023
In Q2, Capitol Counsel LLC lobbied for Genentech , earning $50,000. The report was filed on July 19, 2023.
Original Filing: 301484663.xml
Lobbying Issues
Implementation issues affecting patient access to Medicare covered pharmaceuticals and biologics, including reimbursement adequacy, Medicare Parts B and D benefit parameters, coverage, and reimbursement requirements, including related provisions in H.R. 5376, the Inflation Reduction Act of 2022 (P.L. 117-169): Title 1, Subtitle B - Prescription Drug Pricing Reform: Part 1, Lowering Prices Through Drug Price Negotiation; Part 2, Prescription Drug Inflation Rebates; and Part 3, Part D Improvements and Maximum Out-of-Pocket Cap for Medicare Beneficiaries.
Enhance Center for Medicare & Medicaid Innovation quality initiatives and patient access to Medicare Part B covered drugs, including advocacy related to the Most Favored Nation and related demonstration initiatives.
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B Program issues and patient access to pharmaceuticals, including related provisions in H.R. 3290, to amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program."
Legislative issues associated with patient access to treatment, including: the CMMI Most Favored Nation and related demonstration initiatives; and step therapy, including related provisions in H.R. 2630/S. 652, the Safe Step Act.
Medical Supply Chain, including issues related to a new rating system; targeted action to support the diversification of certain supplies; additional funding to the Strategic National Stockpile (SNS) and more diverse stockpile; increasing flexibility for supply chains.
Enhanced FDA reporting and risk mitigation plans for certain medicines.
Incentives for antimicrobial and antiviral research and novel product development.
Agencies Lobbied
U.S. Senate
1st Quarter, 2023
In Q1, Capitol Counsel LLC lobbied for Genentech , earning $50,000. The report was filed on April 19, 2023.
Original Filing: 301456385.xml
Lobbying Issues
Implementation issues affecting patient access to Medicare covered pharmaceuticals and biologics, including reimbursement adequacy, Medicare Parts B and D benefit parameters, coverage, and reimbursement requirements, including related provisions in H.R. 5376, the Inflation Reduction Act of 2022 (P.L. 117-169): Title 1, Subtitle B - Prescription Drug Pricing Reform: Part 1, Lowering Prices Through Drug Price Negotiation; Part 2, Prescription Drug Inflation Rebates; and Part 3, Part D Improvements and Maximum Out-of-Pocket Cap for Medicare Beneficiaries.
Enhance Center for Medicare & Medicaid Innovation quality initiatives and patient access to Medicare Part B covered drugs, including advocacy related to the Most Favored Nation and related demonstration initiatives.
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B Program issues and patient access to pharmaceuticals. Legislative issues associated with patient access to treatment, including: the CMMI Most Favored Nation and related demonstration initiatives; and step therapy, including related provisions in S. 652, the Safe Step Act.
Medical Supply Chain, including issues related to a new rating system; targeted action to support the diversification of certain supplies; additional funding to the Strategic National Stockpile (SNS) and more diverse stockpile; increasing flexibility for supply chains.
Enhanced FDA reporting and risk mitigation plans for certain medicines.
Incentives for antimicrobial and antiviral research and novel product development.
Agencies Lobbied
U.S. Senate
4th Quarter, 2022
In Q4, Capitol Counsel LLC lobbied for Genentech , earning $60,000. The report was filed on Jan. 19, 2023.
Original Filing: 301435793.xml
Lobbying Issues
Implementation issues affecting patient access to Medicare covered pharmaceuticals and biologics, including reimbursement adequacy, Medicare Parts B and D benefit parameters, coverage, and reimbursement requirements, including related provisions in H.R. 5376, the Inflation Reduction Act of 2022 (P.L.117-169): Title 1, Subtitle B - Prescription Drug Pricing Reform: Part 1, Lowering Prices Through Drug Price Negotiation; Part 2, Prescription Drug Inflation Rebates; and Part 3, Part D Improvements and Maximum Out-of-Pocket Cap for Medicare Beneficiaries.
Enhance Center for Medicare & Medicaid Innovation quality initiatives and patient access to Medicare Part B covered drugs, including advocacy related to the Most Favored Nation and related demonstration initiatives.
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B Program issues and patient access to pharmaceuticals, including monitor related provisions in Sec. 121, H.R. 2471, Consolidated Appropriations Act, 2022, P.L. 117-103.
Coronavirus response efforts, including S. 3799, the PREVENT Pandemics Act, and implementation of related provisions in H.R. 1319, the American Rescue Plan Act (P.L. 117-2).
Legislative issues associated with patient access to treatment, including: the CMMI Most Favored Nation and related demonstration initiatives; and step therapy, including related provisions in S. 464/H.R. 2163, the Safe Step Act.
Medical Supply Chain, including issues related to a new rating system; targeted action to support the diversification of certain supplies; additional funding to the Strategic National Stockpile (SNS) and more diverse stockpile; increasing flexibility for supply chains.
Enhanced FDA reporting and risk mitigation plans for certain medicines, including related provisions in Division F, FDA User Fee Reauthorization Act, of H.R. 6833, providing continuing appropriations for FY 2023.
Incentives for antimicrobial and antiviral research and novel product development, including related provisions in H.R. 3932, to establish a program to develop antimicrobial innovations.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2022
In Q3, Capitol Counsel LLC lobbied for Genentech , earning $60,000. The report was filed on Oct. 19, 2022.
Original Filing: 301412194.xml
Lobbying Issues
Implementation issues affecting patient access to Medicare covered pharmaceuticals and biologics, including reimbursement adequacy, Medicare Parts B and D benefit parameters, coverage, and reimbursement requirements, including related provisions in H.R. 5376, the Inflation Reduction Act of 2022 (P.L.117-169): Title 1, Subtitle B - Prescription Drug Pricing Reform: Part 1, Lowering Prices Through Drug Price Negotiation; Part 2, Prescription Drug Inflation Rebates; and Part 3, Part D Improvements and Maximum Out-of-Pocket Cap for Medicare Beneficiaries.
Enhance Center for Medicare & Medicaid Innovation quality initiatives and patient access to Medicare Part B covered drugs, including advocacy related to the Most Favored Nation and related demonstration initiatives.
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B Program issues and patient access to pharmaceuticals, including monitor related provisions in Sec. 121, H.R. 2471, Consolidated Appropriations Act, 2022, P.L. 117-103.
Coronavirus response efforts, including S. 3799, the PREVENT Pandemics Act, and implementation of related provisions in H.R. 1319, the American Rescue Plan Act (P.L. 117-2).
Legislative issues associated with patient access to treatment, including: the CMMI Most Favored Nation and related demonstration initiatives; and step therapy, including related provisions in S. 464/H.R. 2163, the Safe Step Act.
Medical Supply Chain, including issues related to a new rating system; targeted action to support the diversification of certain supplies; additional funding to the Strategic National Stockpile (SNS) and more diverse stockpile; increasing flexibility for supply chains.
Enhanced FDA reporting and risk mitigation plans for certain medicines, including related provisions in Division F, FDA User Fee Reauthorization Act, of H.R. 6833, providing continuing appropriations for FY 2023.
Incentives for antimicrobial and antiviral research and novel product development, including related provisions in H.R. 3932, to establish a program to develop antimicrobial innovations.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2022
In Q2, Capitol Counsel LLC lobbied for Genentech , earning $60,000. The report was filed on July 20, 2022.
Original Filing: 301389899.xml
Lobbying Issues
Implementation issues affecting patient access to Medicare covered pharmaceuticals and reimbursement adequacy, Medicare Parts B and D benefit parameters, coverage, and reimbursement requirements; use of step therapy in Medicare and health insurance coverage; including related provisions in H.R. 5376 the Build Back Better Act, including provisions regarding Lowering Prices Through Drug Price Negotiation, establishment of a Drug Price Negotiation Program, and Medicare Inflation Rebates, including related provisions in Sections 139001, 139002, 139101, and 139102, and related provisions in the Senate Finance Committee posted amendment to H.R. 5376; and S. 464/H.R. 2163, the Safe Step Act; and antibiotic development incentives, including related provisions in H.R. 4172, P.L. 117-57, to encourage the development and use of certain antimicrobial drugs and H.R. 3932, to establish a program to develop antimicrobial innovations.
Coronavirus response efforts, including S. 3799, the PREVENT Pandemics Act, and implementation of related provisions in H.R. 1319, the American Rescue Plan Act (P.L. 117-2).
Enhance Center for Medicare & Medicaid Innovation quality initiatives and patient access to Medicare Part B covered drugs, including the Most Favored Nation demonstration.
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B Program issues and patient access to pharmaceuticals, including related provisions in Sec. 121, H.R. 2471, Consolidated Appropriations Act, 2022, P.L. 117-103.
Coronavirus response efforts, including S. 3799, the PREVENT Pandemics Act, and implementation of related provisions in H.R. 1319, the American Rescue Plan Act (P.L. 117-2).
Legislative issues associated with patient access to treatment, including the CMMI Most Favored Nation demonstration; and step therapy, including related provisions in S. 464/H.R. 2163, the Safe Step Act.
Medical Supply Chain, including issues related to a new rating system; targeted action to support the diversification of certain supplies; additional funding to the Strategic National Stockpile (SNS) and more diverse stockpile; increasing flexibility for supply chains; enhanced FDA reporting and risk mitigation plans for certain medicines, including related provisions in H.R. 7667, Food and Drug Amendments Act and S. 4348, Food and Drug Administration Safety and Landmark Advancements Act; and improved coordination and expansion of mutual reliance agreements, including implementation of related provisions in H.R. 1319, the American Rescue Plan Act (P.L. 117-2) and H.R. 5376, the Build Back Better Act, Section 31022, Funding for Public Health and Preparedness Research, Development and Countermeasure Capacity, regarding the SNS, supply chains and domestic manufacturing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medical Supply Chain, including issues related to strengthening trade relationships through negotiations with the United States Trade Representative (USTR) and US partners to develop appropriate sources to help secure the US supply chain, along with coordination with trade partners to maintain free movement of goods, including related provisions in H.R. 5376, the Build Back Better Act, Section 31022, Funding for Public Health and Preparedness Research, Development and Countermeasure Capacity, regarding the SNS, supply chains and domestic manufacturing.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2022
In Q1, Capitol Counsel LLC lobbied for Genentech , earning $60,000. The report was filed on April 20, 2022.
Original Filing: 301365179.xml
Lobbying Issues
Implementation issues affecting patient access to Medicare covered pharmaceuticals and reimbursement adequacy, Medicare Parts B and D benefit parameters, coverage, and reimbursement requirements; use of step therapy in Medicare and health insurance coverage; including related provisions in H.R. 5376 the Build Back Better Act, including provisions regarding Lowering Prices Through Drug Price Negotiation, establishment of a Drug Price Negotiation Program, and Medicare Inflation Rebates, including related provisions in Sections 139001, 139002, 139101, and 139102, and related provisions in the Senate Finance Committee posted amendment to H.R. 5376; and S. 464/H.R. 2163, the Safe Step Act; and antibiotic development incentives, including related provisions in H.R. 4172, to encourage the development and use of certain antimicrobial drugs and H.R. 3932, to establish a program to develop antimicrobial innovations.
Coronavirus response efforts, including S. 3799, the PREVENT Pandemics Act, and implementation of related provisions in H.R. 1319, the American Rescue Plan Act (P.L. 117-2).
Enhance Center for Medicare & Medicaid Innovation quality initiatives and patient access to Medicare Part B covered drugs, including the Most Favored Nation demonstration.
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B Program issues and patient access to pharmaceuticals, including related provisions in Sec. 121, H.R. 2471, Consolidated Appropriations Act, 2022.
Coronavirus response efforts, including S. 3799, the PREVENT Pandemics Act, and implementation of related provisions in H.R. 1319, the American Rescue Plan Act (P.L. 117-2).
Legislative issues associated with patient access to treatment, including the CMMI Most Favored Nation demonstration; and step therapy, including related provisions in S. 464/H.R. 2163, the Safe Step Act.
Medical Supply Chain, including issues related to a new rating system; targeted action to support the diversification of certain supplies; additional funding to the Strategic National Stockpile (SNS) and more diverse stockpile; increasing flexibility for supply chains; enhanced FDA reporting and risk mitigation plans for certain medicines; and improved coordination and expansion of mutual reliance agreements, including implementation of related provisions in H.R. 1319, the American Rescue Plan Act (P.L. 117-2) and including related provisions in H.R. 5376, the Build Back Better Act, Section 31022, Funding for Public Health and Preparedness Research, Development and Countermeasure Capacity, regarding the SNS, supply chains and domestic manufacturing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medical Supply Chain, including issues related to strengthening trade relationships through negotiations with the United States Trade Representative (USTR) and US partners to develop appropriate sources to help secure the US supply chain, along with coordination with trade partners to maintain free movement of goods, including related provisions in H.R. 5376, the Build Back Better Act, Section 31022, Funding for Public Health and Preparedness Research, Development and Countermeasure Capacity, regarding the SNS, supply chains and domestic manufacturing.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2021
In Q4, Capitol Counsel LLC lobbied for Genentech , earning $60,000. The report was filed on Jan. 19, 2022.
Original Filing: 301330582.xml
Lobbying Issues
Implementation issues affecting patient access to Medicare covered pharmaceuticals and reimbursement adequacy, Medicare Parts B and D benefit parameters, coverage, and reimbursement requirements; use of step therapy in Medicare and health insurance coverage; including related provisions in H.R. 5376 the Build Back Better Act, including provisions regarding Lowering Prices Through Drug Price Negotiation, establishment of a Drug Price Negotiation Program, and Medicare Inflation Rebates, including related provisions in Sections 139001, 139002, 139101, and 139102, and related provisions in the Senate Finance Committee posted amendment to H.R. 5376; and S. 464/H.R. 2163, the Safe Step Act; and antibiotic development incentives, including related provisions in H.R. 4172, to encourage the development and use of certain antimicrobial drugs and H.R. 3932, to establish a program to develop antimicrobial innovations.
Coronavirus response efforts, including implementation of related provisions in H.R. 1319, the American Rescue Plan Act (P.L. 117-2).
Enhance Center for Medicare & Medicaid Innovation quality initiatives and patient access to Medicare Part B covered drugs, including the Most Favored Nation demonstration.
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B Program issues and patient access to pharmaceuticals.
Coronavirus response efforts, including implementation of related provisions in H.R. 1319, the American Rescue Plan Act (P.L. 117-2).
Legislative issues associated with patient access to treatment, including the CMMI Most Favored Nation demonstration; and step therapy, including related provisions in S. 464/H.R. 2163, the Safe Step Act.
Medical Supply Chain, including issues related to a new rating system; targeted action to support the diversification of certain supplies; additional funding to the Strategic National Stockpile (SNS) and more diverse stockpile; increasing flexibility for supply chains; enhanced FDA reporting and risk mitigation plans for certain medicines; and improved coordination and expansion of mutual reliance agreements, including implementation of related provisions in H.R. 1319, the American Rescue Plan Act (P.L. 117-2) and including related provisions in H.R. 5376, the Build Back Better Act, Section 31022, Funding for Public Health and Preparedness Research, Development and Countermeasure Capacity, regarding the SNS, supply chains and domestic manufacturing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medical Supply Chain, including issues related to strengthening trade relationships through negotiations with the United States Trade Representative (USTR) and US partners to develop appropriate sources to help secure the US supply chain, along with coordination with trade partners to maintain free movement of goods, including related provisions in H.R. 5376, the Build Back Better Act, Section 31022, Funding for Public Health and Preparedness Research, Development and Countermeasure Capacity, regarding the SNS, supply chains and domestic manufacturing.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2021
In Q3, Capitol Counsel LLC lobbied for Genentech , earning $60,000. The report was filed on Oct. 16, 2021.
Original Filing: 301300571.xml
Lobbying Issues
Implementation issues affecting patient access to Medicare covered pharmaceuticals and reimbursement adequacy, Medicare Parts B and D benefit parameters, coverage, and reimbursement requirements; use of step therapy in Medicare and health insurance coverage; including related provisions in the Build Back Better Act, Budget Reconciliation Legislative Recommendations Relating to Drug Pricing, including provisions regarding Fair Drug Price Negotiation and Prescription Drug Inflation Rebates, in Subtitle E, Energy and Commerce, and Subtitle J, Ways and Means, and S. 464/H.R. 2163, the Safe Step Act; and antibiotic development incentives, including related provisions in H.R. 4172, to encourage the development and use of certain antimicrobial drugs and H.R. 3932, to establish a program to develop antimicrobial innovations.
Coronavirus response efforts, including implementation of related provisions in H.R. 1319, the American Rescue Plan Act (P.L. 117-2).
Enhance Center for Medicare & Medicaid Innovation quality initiatives and patient access to Medicare Part B covered drugs, including the Most Favored Nation demonstration.
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B Program issues and patient access to pharmaceuticals.
Coronavirus response efforts, including implementation of related provisions in H.R. 1319, the American Rescue Plan Act (P.L. 117-2).
Legislative issues associated with patient access to treatment, including the CMMI Most Favored Nation demonstration; and step therapy, including related provisions in S. 464/H.R. 2163, the Safe Step Act.
Medical Supply Chain, including issues related to a new rating system; targeted action to support the diversification of certain supplies; additional funding to the Strategic National Stockpile (SNS) and more diverse stockpile; increasing flexibility for supply chains; enhanced FDA reporting and risk mitigation plans for certain medicines; and improved coordination and expansion of mutual reliance agreements, including implementation of related provisions in H.R. 1319, the American Rescue Plan Act (P.L. 117-2) and including related provisions in the Build Back Better Act, Budget Reconciliation Legislative Recommendations Relating to Public Health, Subtitle J, Energy and Commerce, including provisions regarding the SNS, supply chains and domestic manufacturing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medical Supply Chain, including issues related to strengthening trade relationships through negotiations with the United States Trade Representative (USTR) and US partners to develop appropriate sources to help secure the US supply chain, along with coordination with trade partners to maintain free movement of goods, including related provisions in the Build Back Better Act, Budget Reconciliation Legislative Recommendations Relating to Public Health, Subtitle J, Energy and Commerce, including provisions regarding the SNS, supply chains and domestic manufacturing.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2021
In Q2, Capitol Counsel LLC lobbied for Genentech , earning $60,000. The report was filed on July 17, 2021.
Original Filing: 301278675.xml
Lobbying Issues
Implementation issues affecting patient access to Medicare covered pharmaceuticals and reimbursement adequacy, Medicare Parts B and D benefit parameters, coverage, and reimbursement requirements; use of step therapy in Medicare and health insurance coverage; including related provisions in H.R. 3, the Lower Drug Costs Now Act, H.R. 19, the Lower Costs, More Cures Act, and S. 464/H.R. 2163, the Safe Step Act; and antibiotic development incentives, including related provisions in H.R. 4172, to encourage the development and use of certain antimicrobial drugs and H.R. 3932, to establish a program to develop antimicrobial innovations.
Coronavirus response efforts, including implementation of related provisions in H.R. 1319, the American Rescue Plan Act (P.L. 117-2).
Enhance Center for Medicare & Medicaid Innovation quality initiatives and patient access to Medicare Part B covered drugs, including the Most Favored Nation demonstration.
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B Program issues and patient access to pharmaceuticals.
Coronavirus response efforts, including implementation of related provisions in H.R. 1319, the American Rescue Plan Act (P.L. 117-2).
Legislative issues associated with patient access to treatment, including the CMMI Most Favored Nation demonstration; and step therapy, including related provisions in S. 464/H.R. 2163, the Safe Step Act.
Medical Supply Chain, including issues related to a new rating system; targeted action to support the diversification of certain supplies; additional funding to the Strategic National Stockpile (SNS) and more diverse stockpile; increasing flexibility for supply chains; enhanced FDA reporting and risk mitigation plans for certain medicines; and improved coordination and expansion of mutual reliance agreements, including implementation of related provisions in H.R. 1319, the American Rescue Plan Act (P.L. 117-2).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medical Supply Chain, including issues related to strengthening trade relationships through negotiations with the United States Trade Representative (USTR) and US partners to develop appropriate sources to help secure the US supply chain, along with coordination with trade partners to maintain free movement of goods.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2021
In Q1, Capitol Counsel LLC lobbied for Genentech , earning $60,000. The report was filed on April 19, 2021.
Original Filing: 301256402.xml
Lobbying Issues
Implementation issues affecting patient access to Medicare covered pharmaceuticals and reimbursement adequacy, Medicare Parts B and D benefit parameters, coverage, and reimbursement requirements; use of step therapy in Medicare and health insurance coverage. Coronavirus response efforts, including related provisions in H.R. 1319, the American Rescue Plan Act (P.L. 117-2). Enhance Center for Medicare & Medicaid Innovation quality initiatives and patient access to Medicare Part B covered drugs, including the Most Favored Nation demonstration.
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B issues and patient access to pharmaceuticals. Coronavirus response efforts, including related provisions in H.R. 1319, the American Rescue Plan Act (P.L. 117-2). Legislative issues associated with patient access to treatment including the Most Favored Nation demonstration. Medical Supply Chain, including issues related to a new rating system; targeted action to support the diversification of certain supplies; additional funding to the Strategic National Stockpile (SNS) and more diverse stockpile; increasing flexibility for supply chains; enhanced FDA reporting and risk mitigation plans for certain medicines; and improved coordination and expansion of mutual reliance agreements, including related provisions in H.R. 1319, the American Rescue Plan Act (P.L. 117-2).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medical Supply Chain, including issues related to strengthening trade relationships through negotiations with the United States Trade Representative (USTR) and US partners to develop appropriate sources to help secure the US supply chain, along with coordination with trade partners to maintain free movement of goods.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2020
In Q4, Capitol Counsel LLC lobbied for Genentech , earning $70,000. The report was filed on Jan. 21, 2021.
Original Filing: 301244079.xml
Lobbying Issues
Implementation issues affecting patient access to Medicare covered pharmaceuticals and reimbursement adequacy, including related provisions modifying Medicare Parts B and D benefit parameters, coverage, and reimbursement requirements in H.R. 3, the Lower Drug Costs Now Act and S. 2543, the Prescription Drug Pricing Reduction Act; use of step therapy in Medicare and health insurance coverage. Coronavirus response efforts, including related provisions in H.R. 6800, the HEROES Act; H.R. 8406, the Heroes Act; S. 4318, the American Workers, Families, and Employers Assistance Act; S. 4320, the Coronavirus Response Additional Supplemental Appropriations Act, 2020; S. 4322, the Safely Back to School and Back to Work Act; and H.R. 133, the Consolidated Appropriations Act, 2021 - P.L. 116-260. Enhance Center for Medicare & Medicaid Innovation quality initiatives and patient access to Medicare Part B covered drugs, including related provisions in H.R. 5741, the Strengthening Innovation in Medicare and Medicaid Act. Legislative issues associated with patient access to treatment and the Presidents Executive Orders on: (1) Lowering Drug Prices by Putting America First (2) Lowering Prices for Patients by Eliminating Kickbacks to Middlemen (3) Increasing Drug Importation to Lower Prices for American Patients and (4) Access to Life Saving Medications.
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B issues and patient access to pharmaceuticals. Coronavirus response efforts, including related provisions in H.R. 6800, the HEROES Act; H.R. 8406, the Heroes Act; S. 4318, the American Workers, Families, and Employers Assistance Act; S. 4320, the Coronavirus Response Additional Supplemental Appropriations Act, 2020; S. 4322, the Safely Back to School and Back to Work Act; and H.R. 133, the Consolidated Appropriations Act, 2021 - P.L. 116-260. Legislative issues associated with patient access to treatment and the Presidents Executive Orders on: (1) Lowering Drug Prices by Putting America First (2) Lowering Prices for Patients by Eliminating Kickbacks to Middlemen (3) Increasing Drug Importation to Lower Prices for American Patients and (4) Access to Life Saving Medications. Medical Supply Chain, including issues related to a new rating system; targeted action to support the diversification of certain supplies; additional funding to the Strategic National Stockpile (SNS) and more diverse stockpile; increasing flexibility for supply chains; enhanced FDA reporting and risk mitigation plans for certain medicines; and improved coordination and expansion of mutual reliance agreements.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medical Supply Chain, including issues related to strengthening trade relationships through negotiations with the United States Trade Representative (USTR) and US partners to develop appropriate sources to help secure the US supply chain, along with coordination with trade partners to maintain free movement of goods.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2020
In Q3, Capitol Counsel LLC lobbied for Genentech , earning $60,000. The report was filed on Oct. 19, 2020.
Original Filing: 301215011.xml
Lobbying Issues
Implementation issues affecting patient access to Medicare covered pharmaceuticals and reimbursement adequacy, including related provisions modifying Medicare Parts B and D benefit parameters, coverage, and reimbursement requirements in H.R. 3, the Lower Drug Costs Now Act and S. 2543, the Prescription Drug Pricing Reduction Act; use of step therapy in Medicare and health insurance coverage. Coronavirus response efforts, including related provisions in H.R. 6800, the HEROES Act; H.R. 8406, the Heroes Act; S. 4318, the American Workers, Families, and Employers Assistance Act; S. 4320, the Coronavirus Response Additional Supplemental Appropriations Act, 2020; and S. 4322, the Safely Back to School and Back to Work Act. Enhance Center for Medicare & Medicaid Innovation quality initiatives and patient access to Medicare Part B covered drugs, including related provisions in H.R. 5741, the Strengthening Innovation in Medicare and Medicaid Act. Legislative issues associated with patient access to treatment and the Presidents Executive Orders on: (1) Lowering Drug Prices by Putting America First (2) Lowering Prices for Patients by Eliminating Kickbacks to Middlemen (3) Increasing Drug Importation to Lower Prices for American Patients and (4) Access to Life Saving Medications.
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B issues and patient access to pharmaceuticals. Coronavirus response efforts, including related provisions in H.R. 6800, the HEROES Act; H.R. 8406, the Heroes Act; S. 4318, the American Workers, Families, and Employers Assistance Act; S. 4320, the Coronavirus Response Additional Supplemental Appropriations Act, 2020; and S. 4322, the Safely Back to School and Back to Work Act. Legislative issues associated with patient access to treatment and the Presidents Executive Orders on: (1) Lowering Drug Prices by Putting America First (2) Lowering Prices for Patients by Eliminating Kickbacks to Middlemen (3) Increasing Drug Importation to Lower Prices for American Patients and (4) Access to Life Saving Medications. Medical Supply Chain, including issues related to a new rating system; targeted action to support the diversification of certain supplies; additional funding to the Strategic National Stockpile (SNS) and more diverse stockpile; increasing flexibility for supply chains; enhanced FDA reporting and risk mitigation plans for certain medicines; and improved coordination and expansion of mutual reliance agreements.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medical Supply Chain, including issues related to strengthening trade relationships through negotiations with the United States Trade Representative (USTR) and US partners to develop appropriate sources to help secure the US supply chain, along with coordination with trade partners to maintain free movement of goods.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2020
In Q2, Capitol Counsel LLC lobbied for Genentech , earning $60,000. The report was filed on July 17, 2020.
Original Filing: 301191970.xml
Lobbying Issues
Implementation issues affecting patient access to Medicare covered pharmaceuticals and reimbursement adequacy, including related provisions modifying Medicare Parts B and D benefit parameters, coverage, and reimbursement requirements in H.R. 3, the Lower Drug Costs Now Act and S. 2543, the Prescription Drug Pricing Reduction Act; use of step therapy in Medicare and health insurance coverage. Coronavirus response efforts, including related provisions in H.R. 6800, the HEROES Act. Enhance Center for Medicare & Medicaid Innovation quality initiatives and patient access to Medicare Part B covered drugs, including related provisions in H.R. 5741, the Strengthening Innovation in Medicare and Medicaid Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B issues and patient access to pharmaceuticals. Coronavirus response efforts, including related provisions in H.R. 6800, the HEROES Act.
Agencies Lobbied
U.S. Senate
1st Quarter, 2020
In Q1, Capitol Counsel LLC lobbied for Genentech , earning $60,000. The report was filed on April 20, 2020.
Original Filing: 301176725.xml
Lobbying Issues
Implementation issues affecting patient access to Medicare covered pharmaceuticals and reimbursement adequacy, including related provisions modifying Medicare Parts B and D benefit parameters, coverage, and reimbursement requirements in H.R. 3, the Lower Drug Costs Now Act and S. 2543, the Prescription Drug Pricing Reduction Act; use of step therapy in Medicare and health insurance coverage; and legislative efforts to modify the Center for Medicare & Medicaid Innovation to preserve patient access to medically-necessary treatments. Coronavirus response efforts, including related provisions in: (1) H.R. 6074, the Coronavirus Preparedness and Response Supplemental Appropriations Act; (2) H.R. 6201, the Families First Coronavirus Response Act; and (3) H.R. 748, the Coronavirus Aid, Relief, and Economic Security Act. Enhance Center for Medicare & Medicaid Innovation quality initiatives and patient access to Medicare Part B covered drugs, including related provisions in H.R. 5741, the Strengthening Innovation in Medicare and Medicaid Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B issues and patient access to pharmaceuticals. Coronavirus response efforts, including related provisions in: (1) H.R. 6074, the Coronavirus Preparedness and Response Supplemental Appropriations Act; (2) H.R. 6201, the Families First Coronavirus Response Act; and (3) H.R. 748, the Coronavirus Aid, Relief, and Economic Security Act.
Agencies Lobbied
U.S. Senate
4th Quarter, 2019
In Q4, Capitol Counsel LLC lobbied for Genentech , earning $60,000. The report was filed on Jan. 20, 2020.
Original Filing: 301123619.xml
Lobbying Issues
Implementation issues affecting patient access to Medicare covered pharmaceuticals and reimbursement adequacy, including related provisions modifying Medicare Parts B and D benefit parameters, coverage, and reimbursement requirements in H.R. 3, the Lower Drug Costs Now Act and S. 2543, the Prescription Drug Pricing Reduction Act; use of step therapy in Medicare and health insurance coverage; and legislative efforts to modify the Center for Medicare & Medicaid Innovation to preserve patient access to medically-necessary treatments.
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B issues and patient access to pharmaceuticals.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2019
In Q3, Capitol Counsel LLC lobbied for Genentech , earning $60,000. The report was filed on Oct. 21, 2019.
Original Filing: 301077430.xml
Lobbying Issues
Implementation issues affecting patient access to Medicare covered pharmaceuticals and reimbursement
adequacy, and related provisions in S. 2543, the Prescription Drug Pricing Reduction Act, and H.R. 3, the Lower Drug Costs Now Act, including provisions regarding Medicare Parts B and D; and use of step therapy in Medicare and health insurance coverage.
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B issues and patient access to pharmaceuticals.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2019
In Q2, Capitol Counsel LLC lobbied for Genentech , earning $60,000. The report was filed on July 22, 2019.
Original Filing: 301058518.xml
Lobbying Issues
Implementation issues affecting patient access to Medicare covered pharmaceuticals and reimbursement adequacy, and use of step therapy in Medicare and health insurance coverage.
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B issues and patient access to pharmaceuticals.
Agencies Lobbied
U.S. Senate
1st Quarter, 2019
In Q1, Capitol Counsel LLC lobbied for Genentech , earning $60,000. The report was filed on April 21, 2019.
Original Filing: 301032890.xml
Lobbying Issues
Implementation issues affecting patient access to Medicare covered pharmaceuticals and reimbursement adequacy, and use of step therapy in Medicare and health insurance coverage.
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B issues and patient access to pharmaceuticals.
Agencies Lobbied
U.S. Senate
4th Quarter, 2018
In Q4, Capitol Counsel LLC lobbied for Genentech , earning $60,000. The report was filed on Jan. 21, 2019.
Original Filing: 301012527.xml
Lobbying Issues
Implementation issues affecting patient access to Medicare covered pharmaceuticals and reimbursement adequacy, including the proposed CMS Medicare Part B International Pricing Index Model; and use of step therapy in Medicare and health insurance coverage, including related provisions in H.R. 7077, the Restoring the Patients Voice Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B issues and patient access to pharmaceuticals.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2018
In Q3, Capitol Counsel LLC lobbied for Genentech , earning $60,000. The report was filed on Oct. 19, 2018.
Original Filing: 300992027.xml
Lobbying Issues
Implementation issues affecting patient access to Medicare covered pharmaceuticals and reimbursement adequacy; and use of step therapy in Medicare and health insurance coverage, including related provisions in H.R. 7077, the Restoring the Patients Voice Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B issues and patient access to pharmaceuticals.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2018
In Q2, Capitol Counsel LLC lobbied for Genentech , earning $60,000. The report was filed on July 20, 2018.
Original Filing: 300972867.xml
Lobbying Issues
Implementation issues affecting patient access to Medicare covered pharmaceuticals and reimbursement adequacy.
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B issues and patient access to pharmaceuticals.
Agencies Lobbied
U.S. Senate
1st Quarter, 2018
In Q1, Capitol Counsel LLC lobbied for Genentech , earning $60,000. The report was filed on April 19, 2018.
Original Filing: 300952016.xml
Lobbying Issues
Implementation issues affecting patient access to Medicare covered pharmaceuticals and reimbursement adequacy.
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B issues and patient access to pharmaceuticals.
Agencies Lobbied
U.S. Senate
4th Quarter, 2017
In Q4, Capitol Counsel LLC lobbied for Genentech , earning $60,000. The report was filed on Jan. 19, 2018.
Original Filing: 300930779.xml
Lobbying Issues
Implementation of Medicare pharmaceutical coverage and reimbursement; Medicare Part B reimbursement for physicians, and related provisions of the Affordable Care Act. Medicare Part B drug reimbursement adequacy and patient access issues associated with potential CMMI implementation of the proposed Medicare Part B Drug Payment Model.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of the 340B Drug Pricing Program; Issues related to repeal and replacement of the Affordable Care Act, including provisions in H.R. 1628, the American Health Care Act, and proposed Senate substitute amendments, including the Health Care Freedom Act and Senators Graham and Cassidy proposed block grant substitute amendment.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2017
In Q3, Capitol Counsel LLC lobbied for Genentech , earning $60,000. The report was filed on Oct. 20, 2017.
Original Filing: 300915801.xml
Lobbying Issues
Implementation of Medicare pharmaceutical coverage and reimbursement; Medicare Part B reimbursement for physicians, and related provisions of the Affordable Care Act. Medicare Part B drug reimbursement adequacy and patient access issues associated with potential CMMI implementation of the proposed Medicare Part B Drug Payment Model.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of the 340B Drug Pricing Program; Issues related to repeal and replacement of the Affordable Care Act, including provisions in H.R. 1628, the American Health Care Act, and proposed Senate substitute amendments, including the Health Care Freedom Act and Senators Graham and Cassidy proposed block grant substitute amendment.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2017
In Q2, Capitol Counsel LLC lobbied for Genentech , earning $60,000. The report was filed on July 20, 2017.
Original Filing: 300896982.xml
Lobbying Issues
Implementation of Medicare pharmaceutical coverage and reimbursement, Medicare Part B reimbursement for physicians, and related provisions of the Affordable Care Act. Medicare Part B drug reimbursement adequacy and patient access issues associated with potential CMMI implementation of the proposed Medicare Part B Drug Payment Model.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of the 340B Drug Pricing Program; Issues related to repeal and replacement of the Affordable Care Act, including provisions in H.R. 1628, the American Health Care Act, and Senate Discussion Draft of the Better Care Reconciliation Act.
Agencies Lobbied
U.S. Senate
1st Quarter, 2017
In Q1, Capitol Counsel LLC lobbied for Genentech , earning $60,000. The report was filed on April 17, 2017.
Original Filing: 300866932.xml
Lobbying Issues
Implementation of Medicare pharmaceutical coverage and reimbursement, 340B Program, Medicare Part B reimbursement for physicians, and related provisions of the Affordable Care Act. Reimbursement adequacy and patient access issues associated with potential CMMI implementation of the proposed Medicare Part B Drug Payment Model.
Agencies Lobbied
U.S. Senate
4th Quarter, 2016
In Q4, Capitol Counsel LLC lobbied for Genentech , earning $60,000. The report was filed on Jan. 18, 2017.
Original Filing: 300848295.xml
Lobbying Issues
Implementation of Medicare pharmaceutical coverage and reimbursement, 340B Program, Medicare Part B reimbursement for physicians, and related provisions of the Affordable Care Act. Reimbursement adequacy and patient access issues associated with potential CMMI implementation of the proposed Medicare Part B Drug Payment Model, including related provisions in H.R.5122, to prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitor implementation of the National Cancer Moonshot Initiative.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2016
In Q3, Capitol Counsel LLC lobbied for Genentech , earning $60,000. The report was filed on Oct. 20, 2016.
Original Filing: 300839872.xml
Lobbying Issues
Implementation of Medicare pharmaceutical coverage and reimbursement, 340B Program, Medicare Part B reimbursement for physicians, and related provisions of the Affordable Care Act.
Reimbursement adequacy and patient access issues associated with potential CMMI implementation of the proposed Medicare Part B Drug Payment Model.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitor implementation of the National Cancer Moonshot Initiative.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2016
In Q2, Capitol Counsel LLC lobbied for Genentech , earning $60,000. The report was filed on July 19, 2016.
Original Filing: 300813088.xml
Lobbying Issues
Implementation of Medicare pharmaceutical coverage and reimbursement, 340B Program, Medicare Part B reimbursement for physicians, and related provisions of the Affordable Care Act.
Reimbursement adequacy and patient access issues associated with potential CMMI implementation of the proposed Medicare Part B Drug Payment Model.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitor implementation of the National Cancer Moonshot Initiative.
Agencies Lobbied
U.S. Senate
1st Quarter, 2016
In Q1, Capitol Counsel LLC lobbied for Genentech , earning $60,000. The report was filed on April 20, 2016.
Original Filing: 300799775.xml
Lobbying Issues
Implementation of Medicare pharmaceutical coverage and reimbursement, 340B Program, dual eligible demonstrations, Medicare Part B reimbursement for physicians, and related provisions of the Affordable Care Act.
Reimbursement adequacy and patient access issues associated with potential CMMI implementation of the proposed Medicare Part B Drug Payment Model.
Agencies Lobbied
U.S. Senate
4th Quarter, 2015
Capitol Counsel LLC amended a lobbying report for representation of Genentech in Q42015 on Feb. 2, 2016.
Original Filing: 300786004.xml
Lobbying Issues
Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B Program, dual eligible demonstrations, and Medicare Part B reimbursement for physicians, and related provisions of The Affordable Care Act.
Agencies Lobbied
U.S. Senate
4th Quarter, 2015
In Q4, Capitol Counsel LLC lobbied for Genentech , earning $60,000. The report was filed on Jan. 20, 2016.
Original Filing: 300778228.xml
Lobbying Issues
Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B Program, dual eligible demonstrations, and Medicare Part B reimbursement for physicians, and related provisions of The Affordable Care Act.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2015
In Q3, Capitol Counsel LLC lobbied for Genentech , earning $60,000. The report was filed on Oct. 19, 2015.
Original Filing: 300756871.xml
Lobbying Issues
Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B Program, dual eligible demonstrations, and Medicare Part B reimbursement for physicians, and related provisions of The Affordable Care Act.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2015
In Q2, Capitol Counsel LLC lobbied for Genentech , earning $60,000. The report was filed on July 20, 2015.
Original Filing: 300742046.xml
Lobbying Issues
Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B Program, dual eligible demonstrations, and Medicare Part B reimbursement for physicians, and related provisions of The Affordable Care Act.
Agencies Lobbied
U.S. Senate
1st Quarter, 2015
In Q1, Capitol Counsel LLC lobbied for Genentech , earning $60,000. The report was filed on April 20, 2015.
Original Filing: 300727613.xml
Lobbying Issues
Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B Program, dual eligible demonstrations, and Medicare Part B reimbursement for physicians, and related provisions of The Affordable Care Act.
Agencies Lobbied
U.S. Senate
4th Quarter, 2014
In Q4, Capitol Counsel, LLC lobbied for Genentech , earning $60,000. The report was filed on Jan. 19, 2015.
Original Filing: 300701092.xml
Lobbying Issues
Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B Program, dual eligible demonstrations, and Medicare Part B reimbursement for physicians, and related provisions of The Affordable Care Act.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2014
In Q3, Capitol Counsel, LLC lobbied for Genentech , earning $60,000. The report was filed on Oct. 17, 2014.
Original Filing: 300679577.xml
Lobbying Issues
Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B Program, dual eligible demonstrations, and Medicare Part B reimbursement for physicians, and related provisions of The Affordable Care Act.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2014
In Q2, Capitol Counsel, LLC lobbied for Genentech , earning $60,000. The report was filed on July 21, 2014.
Original Filing: 300668146.xml
Lobbying Issues
Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B Program, dual eligible demonstrations, and Medicare Part B reimbursement for physicians, and related provisions of The Affordable Care Act.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2014
In Q1, Capitol Counsel, LLC lobbied for Genentech , earning $60,000. The report was filed on April 17, 2014.
Original Filing: 300638662.xml
Lobbying Issues
Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B Program, dual eligible demonstrations, and Medicare Part B reimbursement for physicians, and related provisions of The Affordable Care Act.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2013
In Q4, Capitol Counsel, LLC lobbied for Genentech , earning $60,000. The report was filed on Jan. 21, 2014.
Original Filing: 300626781.xml
Lobbying Issues
Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B Program, dual eligible demonstrations, and Medicare Part B reimbursement for physicians, and related provisions of The Affordable Care Act.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2013
In Q3, Capitol Counsel, LLC lobbied for Genentech , earning $60,000. The report was filed on Oct. 21, 2013.
Original Filing: 300602846.xml
Lobbying Issues
Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eligiable demonstrations, and Medicare Part B reimbursement for physicians, and related provisions of The Affordable Care Act.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2013
In Q2, Capitol Counsel, LLC lobbied for Genentech , earning $60,000. The report was filed on July 22, 2013.
Original Filing: 300584608.xml
Lobbying Issues
Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eligiable demonstrations, and Medicare Part B reimbursement for physicians, and related provisions of The Affordable Care Act.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2013
In Q1, Capitol Counsel, LLC lobbied for Genentech , earning $60,000. The report was filed on April 22, 2013.
Original Filing: 300560859.xml
Lobbying Issues
Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eligiable demonstrations, and Medicare Part B reimbursement for physicians, and related provisions of The Affordable Care Act.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2012
In Q4, Capitol Counsel, LLC lobbied for Genentech , earning $60,000. The report was filed on Jan. 22, 2013.
Original Filing: 300541582.xml
Lobbying Issues
Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eligiable demonstrations, and Medicare Part B reimbursement for physicians, and related provisions of The Affordable Care Act.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2012
In Q3, Capitol Counsel, LLC lobbied for Genentech , earning $60,000. The report was filed on Oct. 22, 2012.
Original Filing: 300520273.xml
Lobbying Issues
Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, and dual eligiable demonstration related provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Monitoring proposals on U.S. tax treatment of foreign-owned U.S. corporations
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2012
In Q2, Capitol Counsel, LLC lobbied for Genentech , earning $60,000. The report was filed on July 20, 2012.
Original Filing: 300497654.xml
Lobbying Issues
Monitor implementation of Medicare pharmaceutical coverage and reimbursement and 340B provisions of the Affordable Care Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Monitoring proposals on U.S. tax treatment of foreign-owned U.S. corporations
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2012
In Q1, Capitol Counsel, LLC lobbied for Genentech , earning $60,000. The report was filed on April 20, 2012.
Original Filing: 300469481.xml
Lobbying Issues
Monitor implementation of Medicare pharmaceutical coverage and reimbursement and 340B provisions of the Affordable Care Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Monitoring proposals on U.S. tax treatment of foreign-owned U.S. corporations
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2011
In Q4, Capitol Counsel, LLC lobbied for Genentech , earning $60,000. The report was filed on Jan. 19, 2012.
Original Filing: 300445400.xml
Lobbying Issues
Monitor implementation of Medicare pharmaceutical coverage and reimbursement and 340B provisions of the Affordable Care Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Monitoring proposals on U.S. tax treatment of foreign-owned U.S. corporations
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2011
In Q3, Capitol Counsel, LLC lobbied for Genentech , earning $60,000. The report was filed on Oct. 20, 2011.
Original Filing: 300422958.xml
Lobbying Issues
Monitor implementation of Medicare pharmaceutical coverage and reimbursement provisions of the Affordable Care Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Monitoring proposals on U.S. tax treatment of foreign-owned U.S. corporations
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2011
In Q2, Capitol Counsel, LLC lobbied for Genentech , earning $60,000. The report was filed on July 20, 2011.
Original Filing: 300402219.xml
Lobbying Issues
Monitor implementation of Medicare pharmaceutical coverage and reimbursement provisions of the Affordable Care Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Monitoring proposals on U.S. tax treatment of foreign corporations
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2011
In Q1, Capitol Counsel, LLC lobbied for Genentech , earning $60,000. The report was filed on April 20, 2011.
Original Filing: 300375346.xml
Lobbying Issues
Monitor implementation of Medicare pharmaceutical coverage and reimbursement provisions of P.L. 111-148 - Patient Protection and Affordable Care Act and P.L. 111-152 - Health Care and Education Reconciliation Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Monitoring proposals on U.S. tax treatment of foreign corporations.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2010
In Q4, Capitol Counsel, LLC lobbied for Genentech , earning $50,000. The report was filed on Jan. 20, 2011.
Original Filing: 300351493.xml
Lobbying Issues
Monitor implementation of Medicare pharmaceutical coverage and reimbursement provisions of P.L. 111-148 - Patient Protection and Affordable Care Act and P.L. 111-152 - Health Care and Education Reconciliation Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Monitoring proposals on U.S. tax treatment of foreign corporations; S. 506, Stop Tax Haven Abuse Act
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitor changes to outpatient 340B prescription drug discount program, including related provisions included in HR 4994, Medicare & Medicaid Extenders Act.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2010
In Q3, Capitol Counsel, LLC lobbied for Genentech , earning $50,000. The report was filed on Oct. 14, 2010.
Original Filing: 300312939.xml
Lobbying Issues
Monitor implementation of Medicare pharmaceutical coverage and reimbursement provisions of P.L. 111-148 - Patient Protection and Affordable Care Act and P.L. 111-152 - Health Care and Education Reconciliation Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Monitoring proposals on U.S. tax treatment of foreign corporations; S. 506, Stop Tax Haven Abuse Act
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitor changes to outpatient 340B prescription drug discount program, including related provisions included in amendments to HR 4213 - American Jobs and Closing Tax Loopholes Act, and S.3793, Job Creation and Tax Cuts Act.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2010
In Q2, Capitol Counsel, LLC lobbied for Genentech , earning $50,000. The report was filed on July 20, 2010.
Original Filing: 300298960.xml
Lobbying Issues
Monitor implementation of Medicare pharmaceutical coverage and reimbursement provisions of P.L. 111-148 - Patient Protection and Affordable Care Act and P.L. 111-152 - Health Care and Education Reconciliation Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Monitoring proposals on U.S. tax treatment of foreign corporations; S. 506, Stop Tax Haven Abuse Act
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitor changes to outpatient 340B prescription drug discount program, including related provisions included in HR 4213 - American Jobs and Closing Tax Loopholes Act, and draft Senate amendemnts to the legislation.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2010
In Q1, Capitol Counsel, LLC lobbied for Genentech (formerly known as Hoffman-LaRoche, Inc.) , earning $50,000. The report was filed on April 20, 2010.
Original Filing: 300271167.xml
Lobbying Issues
Medicare coverage of and reimbursement for pharmaceuticals, and follow-on biologics, including related provisions in House and Senate comprehensive health reform legislation: HR 3590, Patient Protection and Affordable Care Act, and HR 4872, Health Care and Education Reconciliation Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Monitoring proposals on U.S. tax treatment of foreign corporations; S. 506, Stop Tax Haven Abuse Act
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2009
In Q4, Capitol Counsel, LLC lobbied for Hoffman-La Roche, Inc. , earning $30,000. The report was filed on Jan. 20, 2010.
Original Filing: 300246985.xml
Lobbying Issues
Medicare Part B and Part D coverage of and reimbursement for pharmaceuticals, including oncology, rheumatoid arthritis, ESRD, osteoporosis, diabetes, and access to influenza medications and comparative effectiveness, including related provisions in House and Senate comprehensive health reform legislation; HR 3962, Affordable Health Care for America Act; and HR 3590, Patient Protection and Affordable Care Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Monitoring proposals on U.S. tax treatment of foreign corporations; S. 506, Stop Tax Haven Abuse Act
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2009
In Q3, Capitol Counsel, LLC lobbied for Hoffmann-La Roche, Inc. , earning $60,000. The report was filed on Oct. 20, 2009.
Original Filing: 300216341.xml
Lobbying Issues
Medicare Part B and Part D coverage of and reimbursement for pharmaceuticals, including oncology, rheumatoid arthritis, ESRD, osteoporosis, diabetes, and access to influenza medications and comparative effectiveness, including related provisions in House and Senate comprehensive health reform legislation, HR 3200 and S.1679, America's Affordable Health Choices Act, and the Senate Finance Committee's America's Healthy Futures Act
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2009
In Q2, Capitol Counsel, LLC lobbied for Hoffmann-La Roche, Inc. , earning $60,000. The report was filed on July 16, 2009.
Original Filing: 300179949.xml
Lobbying Issues
Medicare Part B and Part D coverage of and reimbursement for pharmaceuticals, including oncology, rheumatoid arthritis, ESRD, osteoporosis, diabetes, and access to influenza medications and comparative effectiveness, including related provisions in draft House and Senate comprehensive health reform legislation.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2009
In Q1, Capitol Counsel, LLC lobbied for Hoffmann-La Roche, Inc. , earning $60,000. The report was filed on April 20, 2009.
Original Filing: 300162924.xml
Lobbying Issues
Medicare Part B and Part D coverage of and reimbursement for pharmaceuticals, including oncology, rheumatoid arthritis, ESRD, osteoporosis, diabetes, and access to influenza medications and comparative effectiveness.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2008
In Q4, Capitol Counsel, LLC lobbied for Hoffmann-La Roche, Inc. , earning $20,000. The report was filed on Jan. 21, 2009.
Original Filing: 300133012.xml
Lobbying Issues
Medicare Part B and Part D coverage of and reimbursement for pharmaceuticals, including oncology, rheumatoid arthritis, ESRD, osteoporosis, diabetes, and access to influenza medications, comparative effectiveness, and possible related provisions in S. 3101 and HR 6133, Medicare Improvements for Patients and Providers Act.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2008
In Q3, Capitol Counsel, LLC lobbied for Hoffmann-La Roche, Inc. , earning $70,000. The report was filed on Oct. 17, 2008.
Original Filing: 300099151.xml
Lobbying Issues
Medicare Part B and Part D coverage of and reimbursement for pharmaceuticals, including oncology, rheumatoid arthritis, ESRD, osteoporosis, diabetes, and access to influenza medications, comparative effectiveness, and possible related provisions in S. 3101 and HR 6133, Medicare Improvements for Patients and Providers Act.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2008
In Q2, Capitol Counsel, LLC lobbied for Hoffmann-La Roche, Inc. , earning $70,000. The report was filed on July 21, 2008.
Original Filing: 300077170.xml
Lobbying Issues
Medicare Part B and Part D coverage of and reimbursement for pharmaceuticals, including oncology, rheumatoid arthritis, ESRD, osteoporosis, diabetes, and access to influenza medications, comparative effectiveness, and possible related provisions in S. 3101 and HR 6133, Medicare Improvements for Patients and Providers Act.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2008
In Q1, Capitol Counsel, LLC lobbied for Hoffmann-La Roche, Inc. , earning $70,000. The report was filed on July 23, 2008.
Original Filing: 300083693.xml
Lobbying Issues
Medicare coverage of and reimbursement for pharmaceuticals, in Parts B and D, including oncology, rheumatoid arthritis and ESRD
Agencies Lobbied
U.S. House of Representatives
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...